


1A7 Rec'd PCT/PTO 17 APR 2006



TRANSMITTAL LETTER
(General - Patent Pending)

Docket No.
N BG-109

In Re Application Of: Aldo Salimbeni et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/537,731✓	June 6, 2005	Unassigned	48388	Unassigned	7958

Title: PROCESS FOR THE PREPARATION OF BYCYCLIC PEPTIDE COMPOUNDS

COMMISSIONER FOR PATENTS:

Transmitted herewith is:

2 copies of CD's with Sequence Listing; 1 paper copy of Sequence Listing; Pet. 4-month ext. of time; Credit Card Auth. form, Reponse; copy of Notification; postcard. Certificate of mailing dated 4/5/06

in the above identified application.

No additional fee is required.

A check in the amount of _____ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 12-2147 as described below.

Charge the amount of _____

Credit any overpayment.

Charge any additional fee required.

Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Dated: April 5, 2006

Mark D. Lorusso
LORUSSO & ASSOCIATES
3 Pinecrest Terrace
Portsmouth, NH 03801
Tel.: 603-427-0070
Fax: 603-427-5530
Email: mlorusso@liplaw.com

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on April 5, 2006.

(Date)

Signature of Person Mailing Correspondence

Mark D. Lorusso

Typed or Printed Name of Person Mailing Correspondence

CC:

PATENT
ATTORNEY'S DOCKET NO.: NBG-109

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Aldo Salimbeni et al.
Serial No.: 10/537,731
Filed: June 6, 2005
For: PROCESS FOR THE PREPARATION OF BICYCLIC
PEPTIDE COMPOUNDS
Examiner: Not Assigned
Art Unit: Not Assigned

CERTIFICATE OF MAILING

I hereby certify that the following correspondence is being deposited with the United States Postal service as first class mail in an envelope addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313—1450 on April 5, 2006.



Mark D. Lorusso

Commissioner for Patents
PO BOX 1450
Alexandria, VA 22313-1450

RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE
DISCLOSURES

Sir:

This responds to the Notification mailed October 6, 2005. Enclosed herewith are two copies of the Sequence Listing in computer readable format. Another copy of the Sequence Listing in paper form is also enclosed. The content of the Sequence Listing information recorded in computer readable form is identical to the written sequence listing and does not include any new matter.

Respectfully submitted,



Mark D. Lorusso
Reg. No. 41,955
Lorusso & Associates
3 Pinecrest Terrace
Portsmouth, NH 03801
Tel: (603) 427-0070
Attorneys for Applicants

Docket No.: NBG-109

Date: April 5, 2006



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO	FIRST NAMED APPLICANT	ATTY. DOCKET NO
10/537,731	Aldo Salimbeni	NBG-109
INTERNATIONAL APPLICATION NO		
PCT/EP03/13696		
I.A. FILING DATE	PRIORITY DATE	
12/04/2003	12/06/2002	
CONFIRMATION NO. 7958		
371 FORMALITIES LETTER		
 *OC000000017174210*		

Date Mailed: 10/06/2005

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
 CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

INDIA L. EVANS

Telephone: (703) 308-9140 EXT 212

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/537,731	PCT/EP03/13696	NBG-109

FORM PCT/DO/EO/922 (371 Formalities Notice)